TW200602353A - Modified secretin and method of synthesizing thereof - Google Patents

Modified secretin and method of synthesizing thereof

Info

Publication number
TW200602353A
TW200602353A TW094118873A TW94118873A TW200602353A TW 200602353 A TW200602353 A TW 200602353A TW 094118873 A TW094118873 A TW 094118873A TW 94118873 A TW94118873 A TW 94118873A TW 200602353 A TW200602353 A TW 200602353A
Authority
TW
Taiwan
Prior art keywords
peptide
terminus
amino acid
blood component
modified
Prior art date
Application number
TW094118873A
Other languages
Chinese (zh)
Other versions
TWI319766B (en
Inventor
Dominique P Bridon
Alan M Ezrin
Peter G Milner
Darren L Holmes
Karen Thibaudeau
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Priority to TW94118873A priority Critical patent/TWI319766B/en
Publication of TW200602353A publication Critical patent/TW200602353A/en
Application granted granted Critical
Publication of TWI319766B publication Critical patent/TWI319766B/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.
TW94118873A 2000-06-19 2000-06-19 Modified insulin derivatives and conjugates thereof TWI319766B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW94118873A TWI319766B (en) 2000-06-19 2000-06-19 Modified insulin derivatives and conjugates thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW94118873A TWI319766B (en) 2000-06-19 2000-06-19 Modified insulin derivatives and conjugates thereof

Publications (2)

Publication Number Publication Date
TW200602353A true TW200602353A (en) 2006-01-16
TWI319766B TWI319766B (en) 2010-01-21

Family

ID=45073659

Family Applications (1)

Application Number Title Priority Date Filing Date
TW94118873A TWI319766B (en) 2000-06-19 2000-06-19 Modified insulin derivatives and conjugates thereof

Country Status (1)

Country Link
TW (1) TWI319766B (en)

Also Published As

Publication number Publication date
TWI319766B (en) 2010-01-21

Similar Documents

Publication Publication Date Title
EP1623994A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
EP1277762A3 (en) Low allergenic protein variants
AU4934996A (en) Thrombin inhibitors based on the amino acid sequence of hirudin
CA2155185A1 (en) Totally synthetic affinity reagents
DE69840195D1 (en) METHOD AND COMPOSITIONS FOR PREVENTING THE REPRODUCTION OF HIV-1
JP2003508350A5 (en)
EA200100485A1 (en) CONNECTION OF DDS AND METHOD OF ITS MEASUREMENT
CA2331337A1 (en) Site specific protein modification by mutagenesis
WO1996000503B1 (en) Novel peptides
WO2005084179A3 (en) Improved method for preparing conjugates of proteins and chelating agents
AU6898201A (en) Rgd (arg-gly-asp) coupled to (neuro)peptides
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
TW200602353A (en) Modified secretin and method of synthesizing thereof
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO2005041882A3 (en) Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
AU2001292118A1 (en) Dye-labelled peptide and its diagnostic use
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
CA2285700A1 (en) Renin-active substance
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
CA2078000A1 (en) Neutrophil stimulating peptides
DE69827880D1 (en) IGA1-PROTEASE FRAGMENT AS CARRIER PEPTIDE

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees